[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"renal-dysfunction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:renal-dysfunction":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,46,87,119,154],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100635292","contrast-induced-acute-kidney-injury-prevention-in-acute-heart-failure-100635292",false,"NCT07550790","Contrast-Induced Acute Kidney Injury Prevention in Acute Heart Failure","Contrast-Induced Acute Kidney Injury in Acute Heart Failure With Renal Dysfunction: The Kidney Protection Strategies Evaluation in Acute Heart Failure (K-PROSE)","K-PROSE","Inclusion Criteria:\n\n* Adults aged 20 years or older\n* Emergency department visit\u002Fhospitalization for acute heart failure with clinical evidence of congestion\n* Planned contrast-enhanced computed tomography during the index hospitalization\n* Baseline renal dysfunction defined as an estimated glomerular filtration rate (eGFR) of 30-75 mL\u002Fmin\u002F1.73 m²\n\nExclusion Criteria:\n\n* Requirement for vasopressor therapy\n* Requirement for renal replacement therapy (dialysis)\n* Known allergy or hypersensitivity to furosemide\n* Ongoing acute coronary syndrome\n* Pregnant or breastfeeding women, or women of childbearing potential without a negative pregnancy test\n* Hyperkalemia (serum potassium \\>5.5 mmol\u002FL)\n* Uncorrected volume depletion or hyponatremia (serum sodium \\\u003C130 mmol\u002FL)\n* Any condition deemed by the investigator to make participation in the study inappropriate","ALL","20 Years",{"count":20,"type":21},190,"ESTIMATED","INTERVENTIONAL",[24],"NA","The K-PROSE study is a randomized clinical investigation evaluating strategies to prevent contrast-induced acute kidney injury (CI-AKI) in patients hospitalized with acute heart failure and moderate renal dysfunction (eGFR 30-75 mL\u002Fmin\u002F1.73 m²). Patients requiring contrast-enhanced CT imaging are randomized to either standard intravenous saline hydration or a furosemide-based decongestion strategy. Renal function is assessed using serial measurements of creatinine and cystatin C, before and after contrast exposure. By comparing renal outcomes, congestion status, and safety profiles, this study aims to determine whether a decongestion-focused approach provides superior renal protection compared with conventional hydration in high-risk acute heart failure patients.",[27,28],"Heart Failure Acute","Renal Dysfunction",[30,31,32],"contrast-induced acute kidney injury","decongestion","hydration","RECRUITING","2026-04-19",{"date":36,"type":37},"2026-04-24","ACTUAL",{"date":39,"type":21},"2026-05-01",{"date":41,"type":21},"2029-01-30",{"name":43,"class":44},"Seoul National University Bundang Hospital","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":45},"100607172","determination-of-the-prevalence-of-unrecognized-heart-failure-among-patients-at-risk-in-urban-areas-across-germany-using-cmr-100607172","NCT07185100","Determination of the Prevalence of Unrecognized Heart Failure Among Patients at Risk in Urban Areas Across Germany Using CMR","A Prospective, Cross-sectional, Nationwide Community-based Observational Study to Determine the Prevalence of Unrecognized Heart Failure Among Patients at Risk in Urban Areas Across Germany Using CMR","WE-CARE-HF-CMR","Inclusion Criteria:\n\nAsymptomatic subjects with:\n\n* chronic diabetes mellitus (known\u002Fdiagnosed and\u002For antidiabetic medication and\u002For elevated HbA1C) and\u002For\n* renal impairment (known\u002Fdiagnosed CKD and\u002For in laboratory CKD III° or higher) and\u002For\n* Hypertension (known\u002Fdiagnosed and\u002For antihypertensive medication\u002Ftreatment) and\u002For\n* Hypercholesterolaemia (known\u002Fdiagnosed and\u002For antilipid medication\u002Ftreatment) and\u002For\n* Obesity (known\u002Fdiagnosed and\u002For BMI \\> 30 (kg\u002Fm²)) and\u002For\n* Smoker (known\u002Fdiagnosed and\u002For current\u002Fprevious and\u002For medication\u002Ftreatment)\n* Age 40-69 years\n* female or male or diverse sex\n* Ability to provide informed consent\n* Provision of Informed Consent\n\nExclusion Criteria:\n\n* Inability to provide written informed consent\n* Diagnosed heart failure or previously detected reduced ejection fraction\n* General MRI exclusion criteria (pacemaker, defibrillator, intracranial aneurysm clips, metallic foreign bodies in the eyes)\n* Any MRI exclusion criteria not listed here, as determined by the MRI laboratory performing the procedure\n* Haemodynamically unstable participants (heart rate \\\u003C 45\u002Fmin, systolic blood pressure \\\u003C 90 mmHg)\n* Claustrophobia\n* Sensorineural hearing loss of 30 dB or more and tinnitus\n* Acute mental disorders requiring therapy\n* In the presence of pregnancy","40 Years","69 Years",{"count":57,"type":21},600,"OBSERVATIONAL","Heart failure (HF) in patients at risk is often overlooked, and when detected, there is a lack of early and effective preventive interventions. The WE-CARE-HF-CMR study, conducted in large cities\u002Fmetropol areas in Germany ( \\> 1.000.000 inhabitants), aims to close this gap by evaluating the feasibility of a mobile, telemedicinemonitored HF-screening approach combining cardiac magnetic resonance imaging (CMR), quality of life assessment and laboratory tests as key elements in asymptomatic patients at risk. WE-CARE-HF-CMR will provide a proposal for a comprehensive, contemporary screening approach for patients at risk to develop HF tailored to the needs of the target population. This will provide important new information on the prevalence of asymptomatic HF in at-risk patients in urban versus rural areas.\n\nThe results of the study will be compared with the results from the \"HERZCheck'' trial, which provides data from approximately 4,500 participants in rural areas in Germany and has already been completed (NCT05122793).",[61,28,62],"Heart Failure With Preserved Ejection Fraction (HFPEF)","Stage B Heart Failure",[64,65,66,67,68,69,70,71,72,73,74,75,76,77],"Prevention","Heart failure","HFpEF","Asymptomatic","Cardiology","Urban area","Germany","CMR","Cardiac Magnetic Resonance","HFrEF","Diastolic Dysfunction","Strain","mobile","GLS","2026-03-26",{"date":80,"type":37},"2026-04-01",{"date":82,"type":37},"2025-09-13",{"date":84,"type":21},"2036-12-31",{"name":86,"class":44},"German Heart Institute",{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":4,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":17,"minAge":94,"maxAge":95,"enrollmentInfo":96,"targetDuration":4,"studyType":22,"phases":98,"briefSummary":100,"conditions":101,"keywords":105,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":45},"100594523","phase-4-allogeneic-vs-autologous-prp-for-diabetic-wounds-in-renal-dysfunction-a-randomized-controlled-trial-100594523","NCT07020559","Allogeneic vs Autologous PRP for Diabetic Wounds in Renal Dysfunction: a Randomized Controlled Trial","Comparing Allogeneic Versus Autologous Platelet-Rich Plasma for Diabetic Wound Healing in Patients With Renal Dysfunction：a Randomized Controlled Trial","Inclusion Criteria:\n\n1. The patient is aged 18-80 years old;\n2. Diagnosed as type 1 or type 2 diabetes according to the World Health Organization standard, blood sugar has been controlled before enrollment, and the level of Glycated hemoglobin HbA1c is less than 10%;\n3. Abnormal renal function defined as:\n\n   * Serum creatinine \\>106 μmol\u002FL (men) or \\>97 μmol\u002FL (women)\n   * AND eGFR \\\u003C90 mL\u002Fmin\u002F1.73m² (CKD-EPI) ；\n4. The patient has diabetes wounds with poor healing or prolonged healing need standard wound treatment;\n5. After preparing the wound bed, the condition for using platelet plasma to close the wound is met\\*;\n6. Voluntarily sign an informed consent form;\n\nExclusion Criteria:\n\n1. Blood glucose is out of control or not yet effectively controlled，;\n2. Severe diseases such as acute myocardial infarction, heart failure, hepatitis, shock, and respiratory failure have not been corrected yet;\n3. Active bleeding inside the wound, and routine basic treatment plans cannot be implemented；\n4. Uncontrolled systemic or disseminated infections;\n5. Patients with advanced malignant tumors;\n6. Pregnant or lactating women；\n7. The patient is unable to cooperate or has mental disorders;\n8. According to the judgment of the researchers, the patient has a clear and irremovable cause that affects wound healing, which is not suitable for this study or cannot comply with the requirements of this study.","18 Years","80 Years",{"count":97,"type":21},56,[99],"PHASE4","Diabetic wounds are difficult to heal. Autologous platelets in diabetic patients with renal insufficiency have poor function. Allogeneic platelet plasma has a promising application prospect. Comparing the efficacy and safety differences between allogeneic platelet plasma and autologous platelet plasma is of significant importance and value for the clinical application.",[102,103,104,28],"Diabetic Wounds","Platelet Rich Plasma","Allogeneic Blood Transfusions",[106,103,107,108],"Diabetic wounds","allogeneic blood","renal dysfunction","NOT_YET_RECRUITING","2025-08-23",{"date":112,"type":37},"2025-08-26",{"date":114,"type":21},"2026-04",{"date":116,"type":21},"2028-05",{"name":118,"class":44},"Peking University Third Hospital",{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":126,"sex":127,"minAge":128,"maxAge":54,"enrollmentInfo":129,"targetDuration":4,"studyType":22,"phases":131,"briefSummary":132,"conditions":133,"keywords":142,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":153},"100594558","nightware-and-cardiovascular-health-in-women-with-ptsd-100594558","NCT07021014","NightWare and Cardiovascular Health in Women With PTSD","Improving Cardiovascular Health in Women With PTSD by Treating Trauma-Related Nightmares With NightWare","Inclusion Criteria:\n\n* Healthy, as determined by medical history\n* Group Specific Eligibility\n* PTSD Group\n* Lifetime PTSD: screened using Primary Care PTSD Screen for DSM-5 (PC-PTSD-5) and confirmed via Clinician Administered PTSD Scale for DSM-5 (CAPS-5)\n* Prior trauma exposure: screened using Brief Trauma Questionnaire (BTQ)\n* Self-report having repetitive nightmares contributing to disrupted sleep\n* Poor overall sleep quality: PSQI score 6 or higher\n* Control Group\n* No lifetime PTSD: screened using PC-PTSD-5\n* No prior trauma exposure: screened using BTQ\n* Do not self-report having repetitive nightmares contributing to disturbed sleep\n\nExclusion Criteria:\n\n* Pre-existing (e.g., diabetes, liver, kidney disease) or unstable medical condition (e.g., uncontrolled hypertension or active CVD or cancer) or systemic illness that would interfere with interpretation of the study outcomes\n* Body Mass Index ≥ 40 kg\u002Fm2\n* Use of medications that might influence cardiovascular or renal function (i.e., antihypertensive, lipid lowering medications, GLP-1\u002FGIP RAs)\n* Active infection (note, anyone with an active infection would become eligible once the infection has ended)\n* Abnormal thyroid, liver, or kidney function testing during the screening examination or bloodwork. Abnormal kidney function defined as creatinine \\>1.3mg\u002FdL. Abnormal liver function tests within 1.5x ULN. UCH Clinical Lab ULN for AST and ALT are 39 and 52, respectively. Women with TSH levels outside of the normal range (0.5-5.0 mLU\u002FL) will be referred to their PCP and will be allowed study entry once their TSH levels are normalized \\> 3 months\n* Plasma glucose \\>126 mg\u002Fdl under fasting conditions\n* Use of insulin or sulfonylureas\n* Pregnant, within 12 months postpartum or currently breast feeding\n* Current history of substance (excluding marijuana) or alcohol abuse per the SCID-5. Adults with past substance or alcohol use disorders will be allowed to participate.\n* Report elevated acute risk for suicidal self-directed violence warranting immediate hospitalization (e.g., suicidal ideation with intent, evaluated by the C-SSRS).\n* Shift workers\n* Diagnosis of active disorder of arousal from non-rapid eye movement sleep, rapid eye movement sleep behavior disorder, or narcolepsy\n* Nocturia that causes awakening from sleep\n* Epworth Sleepiness Scale: Question #8 score above \"0\" will prompt an additional question: Do you drive (\"get behind the wheel\") when you are drowsy? The answer must be \"No\" to be enrolled in the study due to safety concerns\n* Known sleep walking or acting out dreams (contraindication to NightWare use)\n* Diagnosis or suspicion of dementia\n* Participants experiencing severe cognitive impairment or current psychiatric symptoms of such severity that would preclude participation (e.g., active psychosis, imminently suicidal)\n* Current use of vitamin\u002Fsupplements (including melatonin) or anti-inflammatory medications, participants will be included if they are willing to stop taking vitamin\u002Fsupplements or anti-inflammatory medications 2 weeks prior to the first vascular visit.\n* Current or planned participation in an interventional study during the present study\n* Participants must have access to wireless internet and two power outlets where they sleep",true,"FEMALE","22 Years",{"count":130,"type":21},36,[24],"The purpose of this study is to determine whether NightWare therapeutic intervention improves biomarkers of vascular and renal function in premenopausal women with PTSD-related nightmares, and examine whether these improvements restore them to levels observed in age-matched women without PTSD.",[134,135,136,137,138,139,140,28,141],"Post Traumatic Stress Disorder","Cardiovascular Diseases","Autonomic Dysfunction","Vascular Stiffness","Nightmare","Endothelial Dysfunction","Kidney Diseases","Trauma and Stressor Related Disorders",[143,141,134,135,140,28,136],"Sleep","2025-06-05",{"date":146,"type":37},"2025-06-13",{"date":148,"type":21},"2025-07",{"date":150,"type":21},"2028-07",{"name":152,"class":44},"University of Colorado, Denver",2,{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":158,"acronym":4,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":17,"minAge":94,"maxAge":160,"enrollmentInfo":161,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":163,"conditions":164,"keywords":4,"overallStatus":109,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":4},"100575486","prevalence-of-renal-dysfunction-in-patients-with-chronic-liver-disease-admitted-to-sohag-university-hospital-100575486","NCT06772909","Prevalence Of Renal Dysfunction In Patients With Chronic Liver Disease Admitted To Sohag University Hospital","Inclusion Criteria:\n\n\\- Data regarding demographic variables (age, weight, sex),\n\nEvidence for chronic liver disease is defined by:\n\nA compatible Clinical profile (signs of liver cell failure or reduced liver span) along with Biochemical (altered liver function tests, reversal of albumin globulin ratio, etc) or Sonographic evidence (altered echotexture of the liver) Diuretics will be withheld for 3 days before carrying out lab investigations.\n\nExclusion Criteria:\n\n* • patients \\>70 years\n\n  * Known primary renal disease or obstructive uropathy\n  * Diabetes mellitus\n  * Hypertension","70 Years",{"count":162,"type":21},150,"To find out the prevalence of renal dysfunction in chronic liver disease patients who admitted to sohag university hospital",[28],"2025-01-11",{"date":167,"type":37},"2025-01-14",{"date":169,"type":21},"2025-01",{"date":171,"type":21},"2026-01",{"name":173,"class":44},"Sohag University"]